Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

David G McLeod, Peter Iversen, William A See, Thomas Morris, Jon Armstrong, Manfred P Wirth, Casodex Early Prostate Cancer Trialists' Group

    252 Citationer (Scopus)

    Abstract

    To evaluate, in the ongoing Early Prostate Cancer (EPC) trial programme, the efficacy and tolerability of bicalutamide 150 mg once daily in addition to standard care for localized or locally advanced, nonmetastatic prostate cancer.
    OriginalsprogEngelsk
    TidsskriftBJU International
    Vol/bind97
    Udgave nummer2
    Sider (fra-til)247-54
    Antal sider8
    ISSN1464-4096
    DOI
    StatusUdgivet - 1 feb. 2006

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer'. Sammen danner de et unikt fingeraftryk.

    Citationsformater